Minimally Invasive & Bariatric Surgery — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, training structure, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-25.

Subspecialty fellowship of General Surgery (minimally invasive / bariatric / foregut; Fellowship Council-accredited, non-ACGME). Also called: MIS, MIS/bariatric, Advanced GI/MIS/Foregut. You reach it through general surgery, with a 5-year residency first and then a 1-year fellowship. Organ systems: foregut and metabolic, covering stomach, esophagus, gastroesophageal junction, and abdominal wall; the surgery of weight, reflux, and hernia.

The 30-second version

Minimally invasive & bariatric surgery is the elective, scheduled, tech-forward wing of general surgery. It's the corner of the field where the work is largely planned: laparoscopic and robotic operations on the stomach and esophagus (weight-loss/metabolic surgery, anti-reflux, hiatal hernia) and abdominal-wall hernia repair, instead of the trauma and emergency general surgery that dominate core practice. You book your cases, run your OR days, and outside of complications most of the week can be planned. In exchange for one extra year of training after a general surgery residency, you get pay in the general-surgery-plus range, a meaningfully more controllable surgical lifestyle, and a front-row seat to some of the most dramatic outcomes in medicine, with patients whose type 2 diabetes goes into remission after a metabolic operation. The honest asterisk hanging over the field is the GLP-1 weight-loss drug era, and whether it shrinks bariatric case volume over the next decade (see below; it's a genuine, unresolved debate rather than settled either way).

Quick dashboard (details and sources below)
Training after med school GS residency (5) + MIS/Bariatric fellowship (1) = 6 yrs after med school (7+ if research years taken)
Total from college start ~14 years (4 undergrad + 4 med school + 5 residency + 1 fellowship)
Competitiveness (as a surgical fellowship) Popular, heavily subscribed, many slots — attainable for solid GS grads; ~64% overall FC match rate ⟳
Typical full-time pay ~$500,000–$700,000+ total comp; ~$600K is a reasonable center-of-gravity ⟳
Pay range (structure) ~$450K (25th) → ~$530K (median) → $700K–$900K (top decile), volume-driven ⟳
Lifestyle Mostly elective/scheduled, lighter call than trauma/EGS — but still surgical hours (~55–65/wk)
Burnout Low-to-moderate with high job satisfaction (bariatric-specific survey, 2026) ⟳
% women (fellows) ~31–38% of MIS/bariatric fellows (2015–2019) ⟳
DO / IMG accessibility No fellowship-specific data; gated by the general surgery residency you must finish first ⟳

What they actually do

Minimally invasive surgeons operate on the foregut and the abdominal wall, almost entirely through small incisions, laparoscopically and, increasingly, robotically. The bread-and-butter divides into three durable buckets: bariatric/metabolic surgery (sleeve gastrectomy, gastric bypass, and revisions for weight loss and metabolic disease), foregut/reflux surgery (anti-reflux operations like Nissen fundoplication, hiatal and paraesophageal hernia repair, achalasia myotomy), and hernia/abdominal-wall reconstruction (inguinal, ventral, and complex incisional hernias).1 What ties them together is technique and philosophy: high elective volume, defined case types, and a deliberate move toward planned, ambulatory, technology-enabled operating rather than the unscheduled acute surgery that dominates core general surgery.

The defining feature relative to the rest of general surgery is that most of the work is elective and schedulable. That doesn't make it a light specialty, since attendings still run long OR days plus clinic and rounds, but it means the surgeon controls the calendar to a degree trauma and emergency general surgery (EGS) never allow.2 Metabolic surgery in particular is unusually rewarding on the outcome side: surgeons routinely watch patients reverse diabetes, hypertension, and sleep apnea, and long-term follow-up builds real continuity with patients.3

Representative procedures: laparoscopic and robotic sleeve gastrectomy · Roux-en-Y gastric bypass and revisional bariatric surgery · Nissen/Toupet fundoplication (anti-reflux) · hiatal/paraesophageal hernia repair · Heller myotomy for achalasia · inguinal, ventral, and complex incisional hernia repair (increasingly robotic) · diagnostic and therapeutic upper/lower endoscopy · endoscopic bariatric interventions (sleeve gastroplasty, intragastric balloon, endoscopic revision).41

A day in the life: Most days are OR days. You start with scheduled cases: a robotic hiatal hernia repair, a sleeve, a couple of hernia repairs, docking and undocking the robot between cases (real setup time, but you operate seated and ergonomically). Clinic days are heavy on pre-operative evaluation and long-term post-op follow-up, because bariatric care is a longitudinal relationship, not a one-and-done. Call is lighter and more controllable than a general surgeon carrying a full EGS/trauma rotation, but it isn't zero: post-op bariatric emergencies, whether leaks, bleeds, or obstructions, happen and can't be scheduled.2

The training path & time to completion

This is a subspecialty reached through general surgery, and the training structure has one quirk that comes before anything else: unlike most surgical subspecialties (vascular, pediatric surgery, colorectal), the MIS/bariatric/foregut fellowship is not ACGME-accredited and carries no separate board certificate.5

Medical school (4 yrs) → General Surgery residency (5 yrs, ACGME) → MIS/Bariatric/Foregut fellowship (1 yr, Fellowship Council) = 6 years after med school (7+ if you take dedicated research years in residency).4

  • The non-ACGME Fellowship Council structure. These fellowships are accredited by the Fellowship Council (FC), a consortium that administers accreditation and a centralized match for Advanced GI MIS, Bariatrics, Foregut, Hernia & Abdominal Wall, and related designations. They sit on top of general surgery training as advanced, focused years for "procedures not generally performed in sufficient numbers to achieve competency within the context of General Surgery residency."45
  • No separate ABS certificate. You are board-certified in General Surgery by the American Board of Surgery (ABS). The Fellowship Council states plainly that completing the fellowship "does not fulfill eligibility for board certification." It is advanced training layered on top of general surgery board eligibility rather than its own board pathway.5 There is an ASMBS Fellowship Certificate (a society credential recognizing completion of an accredited bariatric program and minimum case numbers), but that is a training credential rather than a board certification.5
  • Entry is via the Fellowship Council Match. A centralized application and algorithmic rank-list match, structurally like the NRMP but separate from it. A representative cycle: applications open Dec 1, interview offers late February, results released in June.6
  • Case-volume-defined training. Fellowships are competency- and case-count-driven. Advanced GI MIS, for example, requires ~150 complex MIS cases plus endoscopy; Bariatrics requires ≥150 weight-loss operations plus pre-op evaluations and hundreds of post-op encounters. Bariatric host institutions must be MBSAQIP-certified (a bariatric center-of-excellence accreditation).4
  • Total from the start of college: ~14 years (4 undergrad + 4 med school + 5 residency + 1 fellowship).4

How competitive is it? (as a surgical fellowship)

Competitiveness works differently for a fellowship than for a residency you enter straight out of med school. The relevant question is whether a solid general surgery graduate can land an MIS/bariatric spot. The answer is generally yes: it's a popular, heavily subscribed fellowship, but one with an unusually large number of positions and programs.6

  • Scale of the field. In the 2020 Fellowship Council cycle there were 143 certified programs and 265 certified applicants across all FC designations combined; Advanced GI/MIS and MIS/bariatric are the largest single blocks within the FC.67 ⟳
  • Match dynamics. Around the 2020 cycle the overall FC match rate was ~64%, so roughly two-thirds of applicants match. Applicants apply and interview very broadly (median ~27.5 applications submitted, ~10 interviews, ~10 programs ranked), which signals real competition for the desirable programs even though the field as a whole is attainable.6 ⟳
  • The pipeline. About 66% of US general surgery residents pursue a fellowship, a rate stable over the past decade, and MIS is among the higher-volume destinations.6

The honest read: this is a reachable fellowship for a strong general surgery resident, with many slots and broad interest, but the caveat that dwarfs the match itself is that you first have to get through a 5-year general surgery residency, which is its own competitive, demanding road. Current-year (2025–26) FC position counts and fill rates sit behind a member login. ⟳6

Compensation — the robust version

MIS/bariatric is one of the higher-paying corners of general surgery, and its economics are structural, because the single biggest income lever, surgical volume, is exactly what the GLP-1 debate calls into question.

A note on sources first, because it matters here more than usual: there is no large, clean, MIS/bariatric-specific national salary survey. The gold-standard surveys (Doximity, Medscape, BLS) report "General Surgery" as one bucket. Bariatric/MIS-specific numbers come from thinner sources: SalaryDr's bariatric panel is three physicians and its MIS panel fifteen, and MGMA is behind a paywall. Treat the general-surgery benchmarks as the reliable floor and the bariatric-specific figures as directionally high but small-sample.89

The general surgery baseline (reliable). Doximity 2025 puts general surgery at $482,574 (2024 data); Medscape 2025 at ~$434,000; Marit Health at $480,258. BLS "Surgeons, all other" reports a mean of $373,930 (May 2025), but that's a W-2 wage figure that undercounts partnership, bonus, and RVU income, so treat it as a floor rather than a market rate.810 ⟳

The MIS/bariatric-specific number (thinner samples). SalaryDr's "Minimally Invasive General Surgery" bucket reports a median of $495,000 and average of $530,333 (15 self-reported submissions, 2026); its "Bariatric General Surgery" bucket reports a median of $800,000, but off only 3 submissions, so it skews high and should be treated with real skepticism. Marit Health's aggregated "bariatric surgeon" figure is ~$609,000. Lifestyle-side aggregators cluster the average around ~$600K, with a broad ~$400K–$700K+ range.893 ⟳

A defensible read. For a fellowship-trained MIS/bariatric surgeon, expect roughly $450K (25th) → ~$530K (median) → $700K–$900K (top decile), with the top of the range (busy private robotic/bariatric partners) reaching $800K–$900K. A ~$600K center-of-gravity for the fellowship-trained practitioner is reasonable, above the general-surgery baseline.89 ⟳

Starting vs. experienced. New grads often start on a 2–3 year salary guarantee (frequently near $419K–$500K; the Merritt Hawkins recruiter data puts the first-year general surgeon average at ~$419,000), then step to RVU/production-based pay. The big numbers ($700K+) come from private bariatric/foregut partnership tracks where you own the surgical volume and often ancillary and facility revenue, driven by production rather than seniority alone.8 ⟳

Geography. As with most surgical fields, the highest pay tends to be in suburban/rural, high-volume markets with less competition (Mountain West, Upper Midwest) rather than the prestige coastal academic centers, since high-cost coastal metros do not reliably pay more for surgery.8 ⟳

Academic vs. private. The well-established pattern: academic base pay is lower and more predictable, while high-volume private bariatric/robotic practices generate the top numbers because comp tracks case volume plus facility/ancillary economics. (SalaryDr's cut showed hospital-employed ~$575K, academic ~$502.5K, private ~$487.5K, but samples are small and the ranking shouldn't be over-read.)8 ⟳

How you're actually paid, and the income drivers. Hospital-employed bariatric programs typically run salary-guarantee → RVU/production, often bundled into an MBSAQIP center-of-excellence. Robotic foregut/hernia/MIS cases are RVU-rich and robot-intensive, so throughput is the lever. The ambulatory surgery center (ASC) shift adds an earnings angle: surgeons earn ~8–15% more per case in ASC settings, and roughly one in three bariatric procedures now happens in an ASC.82 Locum tenens general surgery runs ~$150–$265/hr.8 ⟳

The trend that colors all of it is GLP-1 drugs. Because MIS/bariatric pay is volume-driven, a sustained bariatric-volume decline is a genuine compensation risk for pure-bariatric surgeons (see the dedicated section below). The common hedges are (a) a broad MIS book of robotic foregut, hernia, and anti-reflux work, so income doesn't ride on bariatric volume alone, and (b) folding medical weight management (GLP-1) into the practice. Fellowship-trained MIS surgeons are well-positioned for the first hedge; pure high-volume bariatric practices carry the most exposure.2

Lifestyle & the elective-surgery bargain

The single most-cited pro of MIS/bariatric relative to core general surgery: most of the work is elective and scheduled. Bariatric, foregut/anti-reflux, and hernia cases are largely planned, so you book your cases, run your OR days, and, outside of complications, control your calendar in a way trauma and EGS general surgery never allows. This is the field's core lifestyle upside, bought with one extra year of training.2

But be clear-eyed: this is not a "lifestyle specialty" in the dermatology or PM&R sense. Attendings still work long OR days plus clinic and rounds, with hours in the general-surgery neighborhood, and roughly 55–65 a week is a reasonable expectation (less than emergency-heavy GS practices, but still surgical).2 The gain is predictability and schedule control, not short hours.

Call is lighter and more controllable than for a general surgeon on a full EGS rotation, and many bariatric-focused practices at dedicated centers or ASCs carry relatively light call. But post-op bariatric emergencies (leaks, bleeds, obstructions) happen and can't be scheduled, so it isn't call-free.2

Two structural tailwinds are improving the day-to-day. The ASC/outpatient shift (outpatient bariatric surgery rose more than 40% in 2022; ~1 in 3 bariatric procedures now happens in an ASC) tends to mean shorter procedure times, faster turnover, and better schedule control. And robotics reshapes the operative day, adding docking and setup time per case (a real workflow cost, especially early on) but lets surgeons operate seated and ergonomically; many describe using the robot deliberately to decompress the schedule and finish the day less physically worn out.2

Lifestyle rating: 3.5/5. Genuinely better schedule control and lighter call than core general surgery, but still real surgical hours and unschedulable post-op emergencies.

Wellbeing — the part to take seriously

Burnout is low-to-moderate, with high job satisfaction, and it's actually measured for this field. The best specialty-specific data is a 2026 Obesity Surgery study of 419 international metabolic/bariatric surgeons (surveyed early 2025). It found low-to-moderate burnout overall and high job satisfaction and resilience: emotional exhaustion and depersonalization were moderate, and most surgeons reported a strong sense of achievement. Burnout clustered in older surgeons and those with poor sleep, low physical activity, and long shifts.3 ⟳

Satisfaction and meaning. Nobody has published a would-choose-again rate by specialty since about 2019, so there is no figure to give here and none is asserted. What is measured here is the 2026 study above, which found high job satisfaction and a strong sense of achievement among bariatric surgeons. The elective, high-reward nature of metabolic surgery, in which you routinely watch patients reverse diabetes, hypertension, and sleep apnea, is a strong meaning-and-satisfaction driver reported across the field.3 ⟳

Career longevity is a genuine edge over open surgery. Minimally invasive and robotic approaches are physically easier on the surgeon than a career of big open cases. That said, laparoscopy carries its own ergonomic toll: in the 2026 survey, 52% of surgeons reported musculoskeletal symptoms despite 95% operating laparoscopically. Robotics is widely seen as the ergonomic answer, letting you operate seated with better posture, which many believe extends operating careers.23 ⟳

A caveat that cuts against the reputation. In the same 2026 survey, 73% reported financial insecurity, a reminder that the "bariatric = money" reputation doesn't guarantee everyone feels secure, and that practice setting, reimbursement, and (increasingly) volume uncertainty all matter.3 ⟳

The patient-stigma weight. Bariatric surgeons routinely treat patients who've faced significant weight stigma, sometimes from other clinicians. Managing patient expectations and long-term follow-up was cited as challenging by over half the surveyed surgeons, but the flip side, durable metabolic reversal, is repeatedly described as among the most rewarding outcomes in surgery.3

Who's in the field (demographics)

Fellowship-specific demographic data is thin, and much of it is only reliably known for the general surgery residency that feeds the fellowship, and IMG/DO/URiM breakdowns specific to MIS/bariatric fellows are not published.

  • Women (fellows, directly measured): ~31% of Advanced GI/MIS fellows and ~38% of MIS/bariatric fellows by the end of a 2015–2019 study window (rising from ~28–29% at its start). Program leadership lags the trainee pool: only ~13.6% of Fellowship Council program directors were women overall (~9.3% in Advanced GI/MIS specifically), ~18.3% of associate program directors, and ~19.9% of faculty. The authors concluded women are underrepresented in GI-surgery fellowships among both trainees and educators.7 ⟳
  • Feeder-pool trend. The female share of US MD matches into general surgery residency rose from ~25% (2015) to ~38% (2024), so the fellow female share tracks the residency pipeline upward.11 ⟳
  • IMG / DO: No MIS/bariatric-fellowship-specific breakdown was located. As a feeder-pool proxy, general surgery residency draws a meaningful share of IMGs and DOs (in the 2024 match, roughly 488 of ~1,772 GS matches were IMGs, and ~221 were US DO seniors). Across all ACGME trainees, the 2023–24 mix was ~58.9% US MD, ~21.9% IMG, ~19.2% DO.11 ⟳
  • URiM: No MIS/bariatric-fellowship-specific underrepresented-in-medicine data was found in public primary sources as of mid-2026, and likely obtainable only via Fellowship Council internal data or custom reports. Limited data.711 ⟳

Culture, personality & the online stereotypes

Who gravitates here: tech-forward surgeons who love laparoscopic and robotic technique and want high elective volume, defined case types, good pay, and a more controllable surgical lifestyle than trauma/EGS offers. It draws people who like the OR but want to plan their week, who enjoy the craft of a clean laparoscopic sleeve, a robotic hernia repair, or a Nissen, and who find deep reward in metabolic disease reversal and long-term patient relationships. As with any culture read, plenty of MIS surgeons don't fit the mold, including academic and complex-revisional specialists whose lives look nothing like an outpatient hernia practice.12

The stereotypes. community reputation, not facts. Each with a kernel of truth and an unfair edge:

  • "Robotic + bariatric = money and a decent surgical lifestyle." The reputation online is that this is one of the better pay-to-lifestyle trades within general surgery: elective, scheduled, well-compensated. There's real truth to it, but "controllable" is not "light," and the pay is volume-dependent.
  • "GLP-1 drugs are coming for bariatric volume." The loudest current read online, and unlike most stereotypes, this one is a genuine, active, unresolved debate rather than a caricature (see below).
  • "Foregut and hernia are the real bread-and-butter." A common online reassurance that even if pure bariatric volume softens, foregut/reflux and hernia and abdominal-wall work provide a durable base, which is why many fellowships now brand as "Advanced GI/MIS/Foregut/Hernia," not just bariatric.

What people say online (synthesized and paraphrased from public discussion, not quoted): The recurring framing is MIS/bariatric as a smart "have your cake and eat it" path within general surgery: you keep operating and earn well, but trade the worst of trauma/EGS call for a schedulable practice. The genuinely contested thread is the GLP-1 debate: some argue drugs will hollow out bariatric volume over the next decade and warn students not to over-index on it; others counter that surgery stays superior for durable results, that drug cost and adherence will drive patients back, and that foregut and hernia work insulate the career, and no one is backing down. The most common piece of practical advice is to build a broad MIS skill set (foregut, hernia, robotics) rather than a pure-bariatric identity, precisely to hedge the volume question. There's enthusiasm for robotics as the field's future, paired with grumbling about docking time, hospital politics over robot access, and cost, and broad agreement that it's more humane than trauma, HPB, and transplant lifestyles while still being real surgery with real hours.

Voices from the field. Paraphrased from public writing, with links to the originals:

  • Dr. Shanu Kothari (Prisma Health), via ACS Clinical Congress News. Acknowledges bariatric procedure declines, and even a program closure tied to anti-obesity drugs, but argues surgery remains superior and the field should adopt a chronic-disease, multimodal model (drugs + surgery), predicting demand rebounds as broad GLP-1 use proves cost-prohibitive.13
  • Dr. David Harris (University of Wisconsin–Madison), via ACS. Optimistic on surgery's viability, arguing medications are "nowhere close" to replacing surgery for durable outcomes.13
  • Dr. Thomas Tsai (Harvard/Brigham), via Mass General Brigham & STAT. The cautious data voice: documents the measurable volume decline and warns of "a high degree of uncertainty," where financial headwinds could damage surgical capacity before demand recovers.1415
  • Drs. Rana Pullatt & Benjamin White, Bariatric Times. On robotics and surgeon longevity: describe using the robot to decompress the schedule and finish less worn out, seeing robotics as key to sustainable careers despite its cost.2

The GLP-1 question — the field's defining career-risk debate

This gets its own section because it's the honest career-risk story a prospective student has to weigh, and because it's the one uncertainty that separates MIS/bariatric from most other surgical subspecialties. Handled evenhandedly: the debate is real and unresolved, and confident people sit on both sides.

The data (why it's a real concern). GLP-1 anti-obesity drugs (semaglutide/Wegovy, tirzepatide/Zepbound) have exploded while bariatric surgery volume has fallen. In a study of ~17 million privately insured Americans, bariatric procedures grew from ~158,000 (2011) to a peak of ~280,000 (2022), then fell ~8.7% from 2022 to 2023 as GLP-1 prescriptions roughly doubled.1415 Longer-cohort figures show the decline continuing: in one insured research cohort, bariatric procedures fell from a 2023 peak of 42,615 to 33,429 in 2025, a ~21.6% drop, while GLP-1 prescriptions in the same cohort rose roughly 310-fold from 2018 to 2025. National headlines in 2026 summarized it as "weight-loss surgeries fall more than 20%."16 ⟳ (Caveat on those counts: the absolute numbers come from specific insured claims cohorts rather than total US procedures, and ASMBS's own national estimates put bariatric procedures near ~270K/yr. The reliable takeaway is the relative direction and magnitude, a 20%+ decline off the 2023 peak, rather than the absolute counts.)16

The optimistic case (why it's not doom). Surgery still beats drugs on durable weight loss, long-term mortality, and cost-effectiveness; continuous GLP-1 use becomes more expensive than surgery within ~9–12 months; adherence and cost may drive patients back; and many surgeons report GLP-1 awareness is actually driving new surgical consults from patients who plateau, regain after stopping the drug, or can't tolerate/afford it. Crucially, ~90–95% of eligible obesity patients still receive no treatment at all, a large untreated pool that limits how much surgery can truly "run out of patients." Several surgeons expect volumes to return toward baseline within 3–5 years, and the field is reframing drugs + surgery as complementary.131517

The cautious case (why the uncertainty is genuine). The pharmaceutical pipeline is deep (oral formulations expected ~2027, extended-release injectables ~2030), drugs will treat vastly more patients than surgery ever could, and financial pressure has already closed at least one hospital bariatric program. The honest read: medical weight loss will dwarf surgery in patient numbers; surgery likely remains a viable, smaller, higher-acuity niche, but the exact future volume is genuinely uncertain.1315

The practical hedge students actually cite: train broad across foregut, hernia, robotics, and bariatric work, so your career doesn't rise or fall on pure bariatric volume. Foregut/reflux and abdominal-wall/hernia demand is not going away, and is unaffected by the GLP-1 debate.2

Why people choose it / why people leave

Why choose it: better schedule control and lighter call than trauma/EGS general surgery (mostly elective, scheduled cases) · strong compensation (~$600K neighborhood, general-surgery-plus) · cutting-edge laparoscopic/robotic technique, with robotics that may extend your operating career · deeply rewarding outcomes (durable reversal of diabetes, hypertension, sleep apnea) and long-term patient relationships · a diversified case base (bariatric + foregut + hernia) with broad, portable demand · only one extra year of training after residency.

Why leave or avoid it: it's still real surgery, with long OR days, meaningful hours, and post-op emergencies that don't wait · the GLP-1 volume question creates genuine, unresolved uncertainty about the future of pure bariatric practice · laparoscopic ergonomic strain is real (MSK symptoms are common), and robot access can be politicized/limited · patient-expectation management and long-term follow-up are demanding · despite the reputation, a notable share of surveyed surgeons report financial insecurity.

Best fit if: you love minimally invasive/robotic technique and want high elective volume with defined case types · you want a controllable surgical lifestyle without leaving the OR · you find metabolic disease reversal and long-term patient care motivating · you're comfortable hedging the GLP-1 uncertainty by building broad MIS/foregut/hernia skills.

Not for you if: you want the adrenaline of trauma and unscheduled acute surgery (go EGS/trauma instead) · you need zero career-volume uncertainty (the GLP-1 debate is unresolved) · you want short hours in an absolute sense (this is controllable, not light) · you dislike technology-dependent workflows (robot docking, platform politics, cost pressures).

The FLI angle — MIS/Bariatric Surgery for first-gen, low-income & immigrant students

Where it fits FLI realities well:

  • Strong pay for a better-than-general-surgery elective lifestyle. For an FLI student who wants surgical income without the full trauma/EGS call grind, this is one of the better pay-to-lifestyle trades in surgery, with roughly $600K-neighborhood earnings with meaningfully more schedule control than core general surgery.
  • Highly marketable, tech-forward, portable skills. Robotic and advanced laparoscopic competence is in demand and portable; foregut and hernia work provide broad, durable job markets across community and academic settings, so you're not tied to a handful of prestige hubs.
  • Only one extra year of training. A 1-year fellowship after a 5-year general surgery residency is a modest income-deferral cost compared with 2+ year fellowships, which matters a lot when you're supporting family and have no financial cushion. And you finish general surgery board-eligible, so the fellowship is additive, not a prerequisite to earning.

Risks to name honestly:

  • The GLP-1 weight-loss-drug uncertainty is the FLI-specific caution. If you build a career narrowly around bariatric case volume, the drug era could soften that base over the next decade, and the data already shows a measurable decline, and the pipeline is deep. For a student with no safety net betting a career on a single case type, that uncertainty is worth taking seriously.
  • The mitigation is real, too. Train broad (foregut + hernia + robotics), and you stay employable and well-paid even if pure bariatric volume shrinks. Foregut/reflux and abdominal-wall/hernia demand is durable.
  • The long road is the real cost. The biggest FLI barrier here is the 5-year general surgery residency you must finish first, on top of med school. That's a long stretch of trainee pay before the strong attending income arrives.

Bottom line: MIS/bariatric offers FLI students an attractive combination: strong surgical pay, a more controllable elective lifestyle, cutting-edge robotic skills, and only one extra training year on top of general surgery. The one honest asterisk is the GLP-1 volume question: hedge it by building a broad minimally invasive skill set rather than a pure-bariatric identity, and it becomes a genuinely FLI-friendly surgical path. Spend time in a real robotic or bariatric OR, and a bariatric clinic, before you commit.

Sub-subspecialty flavors (where the work concentrates)

These are not separate boards but informal concentrations within an MIS/bariatric practice.1

  • Foregut / reflux surgery. Anti-reflux (Nissen/Toupet fundoplication), hiatal/paraesophageal hernia, achalasia (Heller myotomy), GERD workups. Durable, largely elective, and unaffected by the GLP-1 debate, which makes it a key hedge.
  • Hernia / abdominal-wall reconstruction. Inguinal, ventral, and complex incisional hernias, increasingly robotic; extremely high-volume with broad demand. Some surgeons build near-entire practices here.
  • Robotic surgery. Not a disease niche but a platform identity; robotic bariatric, foregut, and hernia work is the growth edge and the ergonomic/longevity play.
  • Endoscopic / endoluminal bariatrics. Newer, less-invasive interventions (endoscopic sleeve gastroplasty, intragastric balloons, endoscopic revision of prior bariatric surgery); a smaller but growing space that overlaps with the drug era rather than only competing with it.

Fun facts

  • Many "bariatric" fellowships have quietly rebranded as "Advanced GI/MIS/Foregut/Hernia," an explicit hedge that broadens the skill set beyond weight-loss surgery.2
  • About one in three bariatric procedures now happens in an ambulatory surgery center rather than a hospital, a big lifestyle-and-earnings shift in barely a decade.2
  • This is one of the few surgical fields where a drug class is the dominant career conversation: GLP-1s are debated in bariatric circles the way AI is debated in radiology.2
  • Robotics is embraced here partly as an ergonomic survival strategy. Surgeons operating seated to protect their own necks, backs, and careers.2
  • Bariatric surgery routinely puts type 2 diabetes into remission. Arguably one of the most dramatic "medicine reversing chronic disease" outcomes in the field, and a major satisfaction driver.3
  • Despite the "money and lifestyle" reputation, a 2026 international survey found 73% of metabolic surgeons reported financial insecurity, so reputation and lived reality don't always match.3
  • Structurally unusual among surgical subspecialties: it's non-ACGME (Fellowship Council-accredited) with no separate board certificate, so you practice as a board-certified general surgeon with advanced fellowship training layered on top.5

Sources

Footnotes

  1. Sub-subspecialty concentrations (foregut, hernia, robotics, endoluminal) and representative procedures. WashU Advanced GI/MIS/Foregut Fellowship (2025), https://mis.wustl.edu/education/; Fellowship Council Designation Descriptions & Criteria (accessed 2026), https://www.fellowshipcouncil.org/designation-descriptions-and-criteria/. ↩ ↩2 ↩3

  2. Lifestyle (elective/scheduled, hours ~55–65/wk, call), ASC/outpatient shift (>40% rise 2022; ~1 in 3 in ASC; ~8–15% more per case), robotics workflow/ergonomics/longevity, fellowship rebranding, and the broad-MIS income hedge. Physicians Thrive, "Trends in Outpatient Bariatric Surgery and Surgeon Earnings" (2024/2026), https://physiciansthrive.com/physician-compensation/bariatric-surgeon/trends-in-outpatient-bariatric-surgery-and-surgeon-earnings/; Bariatric Times (Pullatt & White), "Robotics in Bariatric Surgery: Is the Hype Justified?" (2020), https://bariatrictimes.com/robotics-bariatric-surgery-hype/; WashU (2025), https://mis.wustl.edu/education/. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15

  3. Bariatric-specific burnout/resilience/satisfaction, MSK symptoms (52%), financial insecurity (73%), patient-stigma/expectations, and diabetes remission. Kermansaravi et al., "Beyond the Operating Room: Determinants of Burnout and Resilience among Metabolic Bariatric Surgeons Worldwide," Obesity Surgery 36(6) (2026), https://link.springer.com/article/10.1007/s11695-026-08604-6. Corrected 2026-08-17: this footnote's scope line asserted a general-surgery "would choose again" figure of ~84%, sourced to SalaryDr's General Surgery Work-Life Balance page, on a page whose Wellbeing section says nobody has published a would-choose-again rate by specialty since about 2019 and that none is asserted. The ~84% appeared nowhere in the body, so it was a footnote left behind by the correction that removed the body claim, and it invited a reader who scrolled to conclude the page contradicts itself. The clause is gone, and the SalaryDr citation with it, since nothing else in this footnote's scope rested on it. The bariatric-specific figures all come from Kermansaravi et al. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  4. Training path, 1-year fellowship duration, case-volume requirements, and 6-year post-med-school total. Fellowship Council, Designation Descriptions & Criteria (accessed 2026), https://www.fellowshipcouncil.org/designation-descriptions-and-criteria/; WashU Advanced GI/MIS/Foregut Surgery Fellowship (2025), https://mis.wustl.edu/education/. ↩ ↩2 ↩3 ↩4 ↩5

  5. Non-ACGME Fellowship Council accreditation; no separate ABS certificate (boarded in General Surgery); ASMBS Fellowship Certificate; MBSAQIP host-institution requirement. Fellowship Council, Designation Descriptions & Criteria (accessed 2026), https://www.fellowshipcouncil.org/designation-descriptions-and-criteria/; Fellowship Council Match Listings / Directory (accessed 2026), https://www.fellowshipcouncil.org/directory-of-fellowships/match-listings/; ASMBS Bariatric Fellowship Certificate (accessed 2026), https://asmbs.org/professional-development/fellowship/. ↩ ↩2 ↩3 ↩4 ↩5

  6. Fellowship Council match structure, scale (143 programs / 265 applicants, 2020 cycle), ~64% match rate, application/interview breadth, and ~66% of GS residents pursuing fellowship. Sujka JA et al., "Survey of the 2020 Fellowship Council application and match process and the impact of COVID-19," Surgical Endoscopy (2021/2022), https://link.springer.com/article/10.1007/s00464-021-08935-8; Fellowship Council Matching Process (accessed 2026), https://www.fellowshipcouncil.org/advanced-gi-mis-bariatrics-complex-gastrointestinal-surgery-comprehensive-flexible-endoscopy-foregut-and-hpb-matching-process/; Sun D et al., "Fellowship by the Numbers," J Surg Educ (2025, PMID 39787657), https://pubmed.ncbi.nlm.nih.gov/39787657/. Current-year FC position/fill figures are login-restricted, https://www.fellowshipcouncil.org/matching-process-statistics/. ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  7. Women in MIS/bariatric fellowships (~31% Advanced GI/MIS; ~38% MIS/bariatric, 2015–2019) and program-leadership figures; field scale. Podolsky D et al., "Gender disparities in gastrointestinal surgery fellowship programs," Surgical Endoscopy (2021), https://link.springer.com/article/10.1007/s00464-021-08697-3. ↩ ↩2 ↩3

  8. General surgery baselines, MIS/bariatric-specific pay, starting-vs-experienced, geography, academic-vs-private, employment models, and locums. SalaryDr — Minimally Invasive General Surgery (2026), https://www.salarydr.com/specialty/general-surgery/minimally-invasive; SalaryDr — Bariatric General Surgery (2026), https://www.salarydr.com/specialty/general-surgery/bariatric; Barton Associates — General Surgeon Salary Guide (2026, citing Medscape 2025, BLS 2024, Merritt Hawkins), https://www.bartonassociates.com/general-surgeon-salary-guide/; MGMA 2025 Provider Compensation (paywalled, percentile/wRVU tables to verify), https://www.mgma.com/2025-provider-compensation. SalaryDr panel sizes: n=3, n=15. A self-selected physician panel; the n is disclosed here because it is what the figure rests on. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  9. Doximity general surgery average ($482,574, 2024 data) and metro context; MIS percentile spread. Doximity 2025 Physician Compensation Report, https://www.doximity.com/reports/physician-compensation-report/2025; SalaryDr — Minimally Invasive General Surgery (2026), https://www.salarydr.com/specialty/general-surgery/minimally-invasive; Marit Health — Bariatric Surgeon Salary (2026, aggregator; verify), https://www.marithealth.com/o/-/bariatric-surgeon/salary. On Marit Health: it publishes a panel of self-reported physician salaries, and displays MGMA and AMGA benchmarks beside them that are masked unless you create an account. The figure quoted here comes from the self-reported panel, not from either benchmark. Read it as crowd data: unweighted, of unstated sample size, and directional. SalaryDr appears here only as one item in a source list; no figure on this page rests on it alone. Where a SalaryDr number is used on this page, its panel size is given at the footnote that carries it. ↩ ↩2 ↩3

  10. BLS "Surgeons, all other" (SOC 29-1249) mean wage $373,930 for May 2025, a floor figure, on a median of $414,010, and Medscape general surgeon (~$434,000). US Bureau of Labor Statistics, Occupational Employment and Wages — May 2025, Table 1 (https://www.bls.gov/news.release/archives/ocwage_05152026.htm). Updated 2026-08-18: this figure came from the Occupational Outlook Handbook pay table, which as of 2026-08-18 still prints May 2024 wages. It now comes from the Bureau's May 2025 release, published 2026-05-15. Barton Associates (2026, citing Medscape 2025), https://www.bartonassociates.com/general-surgeon-salary-guide/. ↩

  11. Feeder-pool (general surgery residency) demographics: female share 25%→38% (2015–2024); IMG/DO match figures; all-ACGME trainee mix (2023–24). WifiTalents, "General Surgery Match Statistics" (NRMP/AAMC-derived, 2024; aggregator — verify against NRMP primary), https://wifitalents.com/general-surgery-match-statistics/; ACGME, "2023–2024 Statistics on Graduate Medical Education" (2024), https://www.acgme.org/newsroom/2024/10/acgme-releases-2023-2024-statistics-on-graduate-medical-education-programs-and-resident-physicians/. ↩ ↩2 ↩3

  12. Who gravitates / culture read. Kermansaravi et al., Obesity Surgery (2026), https://link.springer.com/article/10.1007/s11695-026-08604-6; WashU MIS Fellowship overview (2025), https://mis.wustl.edu/education/; synthesized community sentiment from r/surgery, r/medicalschool, and SDN (paraphrased, not individually cited). ↩

  13. GLP-1 debate — optimistic and cautious surgeon perspectives (Kothari, Harris) and complementary-model framing. M. Sophia Newman, "Bariatric Surgeons Consider Sustainability of Bariatric Surgery in the GLP-1 Era," ACS Clinical Congress News (2025), https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/cc2025-news/bariatric-surgeons-consider-sustainability-of-bariatric-surgery-in-glp-1-era/; ACS Bulletin, "Are Anti-Obesity Medications Changing Bariatric Surgery?" (April 2025), https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2025/april-2025-volume-110-issue-4/are-anti-obesity-medications-changing-bariatric-surgery/. ↩ ↩2 ↩3 ↩4

  14. Core volume-decline study: procedures ~158K (2011) → ~280K peak (2022) → −8.7% (2022→2023) as GLP-1 scripts doubled (~17M insured); Tsai's cautious framing. Lin K, Mehrotra A, Tsai TC, "Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management," JAMA Network Open 2024 — a cross-sectional study of 16.8 million commercially and Medicare Advantage insured adults in the OptumLabs Data Warehouse, reporting a more than two-fold rise in GLP-1 RA use as anti-obesity medication from 2022 to 2023 against a relative 8.7% fall in metabolic bariatric surgery. Corrected 2026-08-21: this footnote cited the institution's press release about the study rather than the study; the release's URL now redirects to the newsroom root and the paper is the better citation regardless. Harvard T.H. Chan (2024), https://hsph.harvard.edu/news/rise-in-obesity-drug-use-linked-with-decrease-in-weight-loss-surgery/. ↩ ↩2

  15. GLP-1 debate coverage — decline, uncertainty, and the optimistic counterpoint (cost crossover, adherence, new consults). STAT News, "Bariatric surgery falls as GLP-1 demand rises" (2024), https://www.statnews.com/2024/10/25/bariatric-surgery-falls-as-glp-1-demand-rises-wegovy-zepbound/. ↩ ↩2 ↩3 ↩4

  16. Longer-cohort bariatric volume decline (2023 peak 42,615 → 2025 33,429, ~21.6%), ~310× GLP-1 increase, national headline framing, and the absolute-count caveat. ASMBS, "As GLP-1 Use Skyrockets and Bariatric Surgery Slows" (2025/2026), https://asmbs.org/news_releases/as-glp-1-use-skyrockets-and-bariatric-surgery-slows-most-obesity-goes-untreated/; Harvard T.H. Chan (2026), https://hsph.harvard.edu/news/bariatric-surgeries-on-the-decline-as-use-of-glp-1-drugs-rises/. The absolute national totals are ASMBS estimates. ↩ ↩2

  17. Large untreated obesity pool (~90–95% of eligible patients untreated) and GLP-1-driven new consults (Kurian). ASMBS, "As GLP-1 Use Skyrockets and Bariatric Surgery Slows" (2025/2026), https://asmbs.org/news_releases/as-glp-1-use-skyrockets-and-bariatric-surgery-slows-most-obesity-goes-untreated/; ACS Bulletin, "Are Anti-Obesity Medications Changing Bariatric Surgery?" (April 2025), https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2025/april-2025-volume-110-issue-4/are-anti-obesity-medications-changing-bariatric-surgery/. ↩

Researched with AI assistance and reviewed by hand. How this site is made